Yu J - Search Results

1

Challenges and opportunities in metastatic breast cancer treatments: Nano-drug combinations delivered preferentially to metastatic cells may enhance therapeutic response.

Yu J, Mu Q, Fung M, Xu X, Zhu L, Ho RJY. Yu J, et al. Pharmacol Ther. 2022 Aug;236:108108. doi: 10.1016/j.pharmthera.2022.108108. Epub 2022 Jan 6. Pharmacol Ther. 2022. PMID: 34999182 Free PMC article. Review.

2

Systems Approach to targeted and long-acting HIV/AIDS therapy.

Ho RJ, Yu J, Li B, Kraft JC, Freeling JP, Koehn J, Shao J. Ho RJ, et al. Among authors: yu j. Drug Deliv Transl Res. 2015 Dec;5(6):531-9. doi: 10.1007/s13346-015-0254-y. Drug Deliv Transl Res. 2015. PMID: 26315144 Free PMC article.

3

Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.

Shao J, Kraft JC, Li B, Yu J, Freeling J, Koehn J, Ho RJ. Shao J, et al. Among authors: yu j. Nanomedicine (Lond). 2016;11(5):545-64. doi: 10.2217/nnm.16.1. Epub 2016 Feb 19. Nanomedicine (Lond). 2016. PMID: 26892323 Free PMC article. Review.

4

Translation of combination nanodrugs into nanomedicines: lessons learned and future outlook.

Mu Q, Yu J, McConnachie LA, Kraft JC, Gao Y, Gulati GK, Ho RJY. Mu Q, et al. Among authors: yu j. J Drug Target. 2018 Jun-Jul;26(5-6):435-447. doi: 10.1080/1061186X.2017.1419363. Epub 2018 Jan 10. J Drug Target. 2018. PMID: 29285948 Free PMC article. Review.

5

Novel drug combination nanoparticles exhibit enhanced plasma exposure and dose-responsive effects on eliminating breast cancer lung metastasis.

Mu Q, Yu J, Griffin JI, Wu Y, Zhu L, McConnachie LA, Ho RJY. Mu Q, et al. Among authors: yu j. PLoS One. 2020 Mar 6;15(3):e0228557. doi: 10.1371/journal.pone.0228557. eCollection 2020. PLoS One. 2020. PMID: 32142553 Free PMC article.

6

Controlled Solvent Removal from Antiviral Drugs and Excipients in Solution Enables the Formation of Novel Combination Multi-Drug-Motifs in Pharmaceutical Powders Composed of Lopinavir, Ritonavir and Tenofovir.

Yu J, Yu D, Lane S, McConnachie L, Ho RJY. Yu J, et al. Among authors: yu d. J Pharm Sci. 2020 Nov;109(11):3480-3489. doi: 10.1016/j.xphs.2020.08.003. Epub 2020 Aug 10. J Pharm Sci. 2020. PMID: 32791073 Free PMC article.

7

Novel Long-Acting Drug Combination Nanoparticles Composed of Gemcitabine and Paclitaxel Enhance Localization of Both Drugs in Metastatic Breast Cancer Nodules.

Yu J, Mu Q, Perazzolo S, Griffin JI, Zhu L, McConnachie LA, Shen DD, Ho RJ. Yu J, et al. Pharm Res. 2020 Sep 23;37(10):197. doi: 10.1007/s11095-020-02888-8. Pharm Res. 2020. PMID: 32968837 Free PMC article.

8

ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models.

Zhu L, Mu Q, Yu J, Griffin JI, Xu X, Ho RJY. Zhu L, et al. Among authors: yu j. Pharmaceutics. 2021 Dec 31;14(1):89. doi: 10.3390/pharmaceutics14010089. Pharmaceutics. 2021. PMID: 35056985 Free PMC article.

9

Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression.

Yu J, Xu X, Griffin JI, Mu Q, Ho RJY. Yu J, et al. Cancers (Basel). 2024 Aug 8;16(16):2792. doi: 10.3390/cancers16162792. Cancers (Basel). 2024. PMID: 39199565 Free PMC article.

10

Ursolic Acid in Cancer Treatment and Metastatic Chemoprevention: From Synthesized Derivatives to Nanoformulations in Preclinical Studies.

Zou J, Lin J, Li C, Zhao R, Fan L, Yu J, Shao J. Zou J, et al. Among authors: yu j. Curr Cancer Drug Targets. 2019;19(4):245-256. doi: 10.2174/1568009618666181016145940. Curr Cancer Drug Targets. 2019. PMID: 30332961 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46,200 results

Search Page

Filters